As the founder and CEO of Seattle Genetics, Dr. Clay Siegall brings to the company years of experience in the pharmaceutical industry. His company is focused on developing targeted therapy drugs for a variety of different forms of cancer. They also look to create targeted therapy drugs for other diseases that over the years have not experience significant mortality improvement rates.
Founded in 1998, Seattle Genetics a number of years ago released the very first antibody drug conjugate that was approved by the Federal Drug Administration. This targeted cancer drug treats lymphoma and is now being used in America as well as internationally. Dr. Clay Siegall has formed partnerships with a number of giants in the industry such as Bayer and Pfizer. Through these partnerships his company now has over 20 drugs under development.
When Seattle Genetics was first founded it operated with a very small group of researchers. Dr. Siegall’s leadership has resulted in the company growing by leaps and bounds since that time. It is now a big player in the field of cancer research and has ambitious plans for the future. The ultimate goal is the elimination of cancer through targeted drug therapies. This next-gen approach to cancer is much more effective and safe than older, conventional methods of treating cancer. The drugs that Dr. Siegall and his team come up with only destroy cancer cells so they leave healthy cells completely alone.
It was while attending the University of Maryland and pursuing his zoology degree that Dr. Clay Siegall decided to instead steer his course towards cancer research. One of the members of his family was diagnosed with cancer and Dr. Siegall saw up close how brutal the treatment regimen was that they had to go through. He said that this family member almost died but it was due to the chemotherapy they were going through rather than the cancer itself. He ended up attending George Washington University and earning a Ph.D. in genetics.
In addition to his role at Seattle Genetics, Dr. Siegall provides his leadership at a number of other organizations. He is a director at three other firms in the industry and had been named Entrepreneur of the Year in 2012.